Epidemiological profile of invasive bacterial diseases in children in Casablanca, Morocco: antimicrobial susceptibilities and serotype distribution

East Mediterr Health J. 2012 Nov;18(11):1097-101. doi: 10.26719/2012.18.11.1097.

Abstract

The aim of this prospective study in Morocco was to investigate the causes of invasive bacterial diseases in children in order to inform antibiotic therapy and vaccine choices. Of 238 children aged < or = 5 years admitted to the Children's Hospital of Casablanca for invasive diseases over a 12-month period, 185 were diagnosed with bacterial infection: 76 had chest-X-ray-confirmed pneumonia, 59 had meningitis and 50 had sepsis. Streptococcus pneumoniae was the most common pathogen identified (n = 24), followed by Neisseria meningitidis (n = 18, all group B) and Haemophilus influenzae (n = 11). The rate of penicillin non-susceptibility was 62.5% among Str. pneumoniae isolates and 11.1% among N. meningitidis and all isolates were ceftriaxone-susceptible. Of the 11 H. influenzae isolates, only 1 produced a beta-lactamase. The 5 predominant Str. pneumoniae serotypes were 19F, 14, 23F, 6B and 19A and the theoretical coverage of the 7, 10 and 13-valent pneumococcal conjugate vaccines was 60%, 78% and 91% respectively.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anti-Bacterial Agents / pharmacology*
  • Anti-Bacterial Agents / therapeutic use
  • Bacterial Infections / drug therapy
  • Bacterial Infections / epidemiology*
  • Bacterial Infections / microbiology*
  • Child, Preschool
  • Drug Resistance, Microbial*
  • Female
  • Haemophilus influenzae type b / drug effects
  • Haemophilus influenzae type b / genetics
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Morocco / epidemiology
  • Neisseria meningitidis / drug effects
  • Neisseria meningitidis / genetics
  • Pneumococcal Vaccines / immunology
  • Prospective Studies
  • Serotyping
  • Streptococcus pneumoniae / drug effects
  • Streptococcus pneumoniae / genetics

Substances

  • Anti-Bacterial Agents
  • Pneumococcal Vaccines